

Grand Rounds

Friday, February 23, 9:00am

Targeting Apoptosis in Leukemia: lessons and challenges

featuring

Marina Konopleva, MD, PhD

**Professor, Departments of Oncology and Molecular
Pharmacology; Miriam Mandel Faculty Scholar in
Cancer Research, Albert Einstein College of Medicine**

55 Park Street Auditorium | [Zoom](#) Access
Continental breakfast will be available

Needs: Understanding current utility of BCL-2 inhibitors in malignant hematology indications. Learning about known resistance mechanisms and combination strategies.

Objectives: Review of approved indications for venetoclax in AML. Analysis of ongoing combination trials with chemotherapy, targeted agents and immune therapies. Management of side effects and strategies of preventing myelosuppression.



Continuing Medical Education
Yale CME



Dr. Marina Konopleva is a Professor in the Departments of Oncology and Molecular Pharmacology and a Miriam Mandel Faculty Scholar in Cancer Research at the Albert Einstein College of Medicine. She received her Doctor of Medicine from First Pavlov Medical Institute in St. Petersburg, Russia, and obtained her PhD in experimental hematology from the Federal Institute of Hematology and Blood Transfusion.

Dr. Konopleva's groundbreaking research focuses on treating patients with hematologic malignancies, with an emphasis on acute myeloid and acute lymphoblastic leukemias. She has additional expertise in treating patients with high-risk myelodysplastic syndromes and chronic myeloid leukemia. Her work has greatly benefited leukemia research, clinical research, and the lives of patients. She is a scholar of the Leukemia & Lymphoma Society, and her research is funded by the National Institutes of Health, Department of Defense, and various private foundations.